Company news
hVIVO plc news in 2022
hVIVO plc's news releases, calls and decks from 2022, newest first.
Imutex Phase I data published
December 19, 2022
hVIVO hails growing contract values after winni...
November 14, 2022
£13.6m RSV antiviral contract
November 10, 2022
Change of name to hVIVO plc effective
October 25, 2022
Capital Markets Day
October 20, 2022
CFO appointment & change of Board roles
October 18, 2022
Positive in vitro results for FLU-v published
September 30, 2022
Upcoming Scientific Presentations
September 27, 2022
Comment regarding press speculation
September 15, 2022
Interim results and trading update
September 8, 2022
CAP accreditation
September 1, 2022
£10.4m contract with existing Big Pharma client
August 22, 2022
£6.2m Influenza human challenge study contract
August 4, 2022
Omicron human challenge model
June 30, 2022
£7.2m RSV human challenge study contract
June 14, 2022
Board appointment amendment
June 10, 2022
Board appointment
June 8, 2022
GBP14.7m influenza contract signed
June 1, 2022
Completion of Nominated Adviser due diligence
May 26, 2022
£7.3m Influenza human challenge study contract win
May 18, 2022
Wellcome publication
May 12, 2022
Vaccine field study contract
May 5, 2022
Challenge virus manufacturing contract
May 4, 2022
Appointment of Nominated Adviser and Joint Broker
April 28, 2022
Proposal to Distribution in Specie Shareholders
April 13, 2022
Characterisation Study results in Nature Medicine
March 31, 2022
£5m RSV human challenge study contract win
March 25, 2022
Trading Update and screening facilities expansion
March 8, 2022
Investor Presentations
March 2, 2022
CEO Appointment
February 24, 2022
FDA Breakthrough Designation for Big Pharma RSV
February 22, 2022
Positive results from RSV Human Challenge Study
February 17, 2022
Launch of STRiVE project
February 14, 2022
World's first COVID-19 Characterisation Study
February 2, 2022
Malaria Human Challenge Model Launched
January 20, 2022
Calls in 2022
Decks in 2022
- H1 2022 Earnings Presentation
Earnings · 27 slides · September 2022
- Open Orphan — Investor Presentation (March 2022)
Investor deck · 15 slides · March 2022